CStone Pharmaceuticals (HK:2616) has released an update.
CStone Pharmaceuticals has announced that its partner Jiangsu Hengrui Pharmaceuticals Co., Ltd. has begun a Phase III clinical trial for an anti-CTLA-4-based combination therapy as a first-line treatment for advanced hepatocellular carcinoma. The trial will assess the efficacy and safety of their investigational antibody, CS1002, in combination with other drugs, compared to existing treatments. CStone’s strategic partnership with Hengrui could lead to milestone payments up to approximately $200 million plus royalties, with CStone retaining rights outside Greater China.
For further insights into HK:2616 stock, check out TipRanks’ Stock Analysis page.
